Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

Volltext
Verfasser: R. J. S. D. Heine
F. W. Thielen
R. H. J. Mathijssen
R. W. F. van Leeuwen
M. G. Franken
C. A. Uyl-de Groot
Dokumenttyp: Image
Erscheinungsdatum: 2024
Schlagwörter: Biotechnology / Ecology / Cancer / Science Policy / Infectious Diseases / Plant Biology / Computational Biology / smaller patient populations / larger patient populations / already approved immuno / sensitivity analysis showed / lower estimates resulted / l &# 246 / deterministic stepwise analysis / eligible patient population / daratumumab per vial / pembrolizumab per vial / daratumumab &# 8217 / xlink \ / > expanding / profit margin contributed / pembrolizumab (&# 8364 / modeled cbps depending / dutch list prices / based pricing models / indication (&# 8364 / assumed lower r / yearly cumulative cost / daratumumab </ p / based pricing model / &# 8364 / > / profit margin / based pricing / scenario analysis / consistently lower / pharmaceutical pricing / cumulative indication / based prices / study focuses / significant influence / significant impact / registered indications / potential effect / ongoing discussions / model proposed / initial years / initial r / indications due / indication expansion / indication broadening
Sprache: unknown
Permalink: https://search.fid-benelux.de/Record/base-29034491
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.1371/journal.pone.0293264.g004